Literature DB >> 6683

Evaluation of the binding of some substituted anthraquinones and naphthacenequinones to DNA.

J C Double, J R Brown.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 6683     DOI: 10.1111/j.2042-7158.1976.tb04122.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


× No keyword cloud information.
  6 in total

1.  Mitoxantrone hydrochloride (NSC-310739) in lymphoma. A Southwest Oncology Group study.

Authors:  C A Coltman; T M McDaniel; S P Balcerzak; F S Morrison; D D Von Hoff
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

2.  Mitoxantrone: an overview of safety and toxicity.

Authors:  L E Posner; G Dukart; J Goldberg; T Bernstein; K Cartwright
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

3.  Pharmacology of mitoxantrone in cancer patients.

Authors:  N Savaraj; K Lu; V Manuel; T L Loo
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

4.  Mitoxantrone in combination with prednimustine in treatment of unfavorable non-Hodgkin lymphoma.

Authors:  K E Landys
Journal:  Invest New Drugs       Date:  1988-06       Impact factor: 3.850

5.  Mitoxantrone in the treatment of relapsed and refractory acute leukemia.

Authors:  P Meyer; A D Ho; G Ehninger; I Mjaaland; E Heidemann; E Seither
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

Review 6.  Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent.

Authors:  L H Patterson
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.